Frat1 demonstrates oncogenic properties in prostate cancer by inhibiting GSK 3β against β-catenin and thus promoting cell growth (Zhang et al., 2016), while Frat2 mediates the oncogenic activation of Rac by mixed lineage leukemia fusions (Walf-Vorderwulbecke et al., 2012). The gene discussed is FRAT1; the disease is prostate carcinoma.